Gosselies, Belgium, 7 May 2019, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today provides a business update for the first quarter ended 31 March 2019.
Thomas Lienard, Chief Executive Officer of Bone Therapeutics commented: “We are well-positioned to support long term growth with ALLOB, our cutting-edge allogeneic cell therapy platform, as well as JTA-004, our innovative viscosupplement addressing unmet needs in osteoarthritis. We are on track to report the data from the Phase IIa ALLOB study in patients undergoing a spinal fusion procedure before the summer. Following the strong Phase IIa results with ALLOB in patients with delayed union fractures and JTA-004 to treat pain in patients with knee osteoarthritis, we are now preparing the start of two late-stage clinical programs for which we expect to file clinical trials applications later this year. Our competitive, scalable, proprietary cell therapy manufacturing process is now optimised and representative of future commercial scale. With the appointments of Olivier Godeaux as Chief Medical Officer and Benoit Moreaux as Chief Scientific and Technology Officer, we now have a leadership team in place to execute our growth strategy and we are looking forward to updating the market on the progress we make.”
Corporate highlights
- Presented in vitro and in vivo data for ALLOB at the Annual Meeting of the Orthopaedic Research Society (ORS), demonstrating the potent osteogenic properties of ALLOB to promote direct bone-formation and to improve fracture healing in relevant models.
- Strengthened the executive management team with the appointments of Olivier Godeaux, MD, as Chief Medical Officer and Benoît Moreaux, PhD, as Chief Scientific and Technology Officer.
Financial highlights
- Achieved a regulatory milestone as part of its PREOB collaboration with Asahi Kasei, triggering a € 1 million success fee. In parallel, Asahi Kasei and the Company are reviewing their options regarding the future of the PREOB licensing agreement, following termination of the PREOB study in osteonecrosis of the hip in Europe.
- Good cost and cash management will remain a key priority. The net cash burn for the full year 2019 is expected to be in the range of € 12-13 million. The Company anticipates having sufficient cash to carry out its business objectives until the end of 2019, taking into account the € 3.75 million to be received under the convertible bond programme.
- As a result, the Company ended the first quarter of 2019 with a cash balance of € 7.13 million.
Outlook for the remainder of 2019
- The Company expects to report in mid-June top line data from the Phase IIa study with ALLOB in patients undergoing a lumbar spinal fusion procedure.
- The company will participate to the Belgian Life Science day organised by Kepler Cheuvreux in collaboration with Belfius in Paris on 18 June.
- In the second half of 2019, the Company plans to submit a clinical trial application (CTA) with the regulatory authorities in Europe and the United States to allow the start of a Phase II/III clinical trial with ALLOB in patients with delayed-union fractures, using its proprietary, optimised production process.
- Also, in the second half of 2019, the Company plans to submit a CTA with the regulatory authorities in Europe and the United States for the Phase III programme with JTA-004 in patients with knee osteoarthritis.
About Bone Therapeutics
Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy and an innovative biological product in later-stage clinical development across a number of disease areas, which target markets with large unmet medical needs and limited innovation.
Bone Therapeutics’ core technology is based on its allogeneic cell therapy platform (ALLOB) which uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, cutting-edge manufacturing process.
The Company’s ALLOB product pipeline includes a cell therapy product candidate that is expected to enter Phase II/III clinical development for the treatment of delayed-union fractures and a Phase II asset in patients undergoing a spinal fusion procedure. In addition, the Company is also developing an enhanced viscosupplement, JTA-004, which is expected to enter Phase III development for the treatment of pain in knee osteoarthritis.
Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a broad IP portfolio covering nine patent families as well as knowhow. Further information is available at www.bonetherapeutics.com.
Contacts
Bone Therapeutics SA
Thomas Lienard, Chief Executive Officer
Jean-Luc Vandebroek, Chief Financial Officer
Gunther De Backer, Head of Corporate Communications and Investor Relations
Tel: +32 (0) 71 12 10 00
investorrelations@bonetherapeutics.com
International Media Enquiries:
Consilium Strategic Communications
Marieke Vermeersch
Tel: +44 (0) 20 3709 5701
bonetherapeutics@consilium-comms.com
For French Media and Investor Enquiries:
NewCap Investor Relations & Financial Communications
Pierre Laurent, Louis-Victor Delouvrier and Nicolas Merigeau
Tel: + 33 (0)1 44 71 94 94
bone@newcap.eu
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors` current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person`s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
